297. Alagille syndrome Clinical trials / Disease details


Clinical trials : 43 Drugs : 19 - (DrugBank : 9) / Drug target genes : 2 - Drug target pathways : 2

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000996-36-IT
(EUCTR)
09/11/202127/01/2022A long term Investigation of the Safety and Efficacy of Odevixibat in Patients with Alagille syndromeAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT) - NA Alagille Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10053870;Term: Alagille syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Other descriptive name: A4250
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Other descriptive name: A4250-015
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Other descriptive name: A4250
Product Name: Odevixibat
Product Code: [A4250]
INN or Proposed INN: Odevixibat
Other descriptive name: A4250
ALBIREO ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3United States;Turkey;Israel;Italy;United Kingdom;France;Canada;Belgium;Malaysia;Poland;Germany;Netherlands;New Zealand